Atezolizumab市场：按药物类别、按适应症、按配销通路、按最终用户、按地区

预计2023年全球Atezolizumab市场规模为26.8亿美元，预计2030年将达78.6亿美元，2023年至2030年年复合成长率(CAGR)为16.6%。

图 1. Atezolizumab全球市场占有率(%)（按地区），2022 年

Atezolizumab是一种突破性免疫疗法药物，彻底改变了癌症治疗。它可以单独使用或与其他化疗药物合併使用来治疗成人某些类型的非小细胞肺癌（NSCLC）。 Atezolizumab注射液属于一类称为单株抗体的药物。这种治疗性抗体由罗氏公司开发，可抑製程序性死亡配体 1 (PD-L1) 蛋白，可使癌细胞逃避免疫系统的检测。透过抑制 PD-L1， Atezolizumab释放免疫系统辨识和攻击癌细胞的能力，从而改善患者的预后。 Atezolizumab注射液也与其他化疗药物合併用于治疗成人某些类型的小细胞肺癌 (SCLC)、肝细胞癌 (HCC) 和黑色素瘤（一种皮肤癌）。 Atezolizumab也可单独用于治疗成人和 2 岁以上儿童的某些类型的肺泡软组织肉瘤（肌肉癌、脂肪癌和神经癌）。

市场动态：

由于几个关键因素，Atezolizumab市场正在经历显着成长。首先，全球癌症发生率的上升增加了对有效治疗方案的需求。 Atezolizumab在多种癌症（包括肺癌、膀胱癌和乳腺癌）中显示出有希望的结果，扩大了可治疗的患者群体。此外，人们对免疫疗法益处的认识不断提高以及对标靶治疗的偏好正在进一步推动市场成长。

然而，儘管机会众多，但也存在着限制市场的因素。 Atezolizumab的高价是一个主要障碍，限制了低收入国家甚至一些新兴市场的患者获得该药物。此外，新药核准流程复杂且耗时，为市场准入带来了挑战。此外，替代免疫疗法和生物相似药的出现也可能阻碍市场成长。

不过， Atezolizumab市场未来市场开拓潜力大。诺华、辉瑞、默克、阿斯特捷利康、百时美施贵宝、百济神州、信达生物、基因泰克和艾伯维等主要企业的研发努力将带来创新治疗方法和进一步的市场扩张。对精准医疗的日益关注和伴同性诊断的发展也为使用Atezolizumab的个体化治疗方法创造了机会。

本研究的主要特点

• 本报告对全球Atezolizumab市场进行了详细分析，包括以2022年为基准年的预测期（2023-2030）的市场规模和复合年增长率。
• 它还揭示了各个细分市场的潜在商机，并为该市场说明了一系列有吸引力的投资提案。
• 它还提供了有关市场驱动因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要考察。
• 本研究介绍的全球Atezolizumab市场的主要企业包括罗氏、诺华、辉瑞、默克、阿斯特捷利康、百时美施贵宝、百济神州、信达生物、基因泰克、艾伯维等。
• 该报告的见解使行销人员和负责人能够就未来的产品发布、升级、市场扩张和行销策略做出资讯的决策。
• Atezolizumab全球市场报告面向产业内的各个相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
• 透过用于分析全球Atezolizumab市场的各种策略矩阵，将有助于相关人员做出决策。

目录

第一章 研究目的与假设

• 研究目标
• 假设
• 简称

第二章 市场展望

• 报告说明
  • 市场定义和范围
• 执行摘要
• Coherent Opportunity Map（COM）

第三章市场动态、法规及趋势分析

• 市场动态
  • 促进因素
• 全球癌症发生率增加
• 对有效治疗方案的需求增加
  • 抑制因素
• Atezolizumab的高成本
  • 机会
• 主要企业持续研发配合措施
• 影响分析
• 主要亮点
• 监管场景
• 产品发布/核准
• PEST分析
• 波特的分析
• 併购场景

第四章全球Atezolizumab市场 -冠状病毒(COVID-19) 大流行的影响

• 新型冠状病毒感染疾病（COVID-19）的流行病学
• 供需面分析
• 经济影响

第 5 章 全球Atezolizumab市场，依药物类别，2018-2030

• 介绍
• PD-L1抑制剂
• PD-1抑制剂
• CTLA-4抑制剂
• 免疫调节剂
• 其他的

第六章 全球Atezolizumab市场，依适应症分类，2018-2030 年

• 介绍
• 肺癌
• 膀胱癌
• 黑色素瘤
• 霍奇金淋巴瘤
• 头颈癌
• 其他的

第 7 章全球Atezolizumab市场，依配销通路划分，2018-2030 年

• 介绍
• 医院药房
• 零售药房
• 线上药房

第 8 章全球Atezolizumab市场，按最终用户划分，2018-2030 年

• 介绍
• 医院
• 居家医疗
• 专科诊所
• 其他的

第9章全球Atezolizumab市场，按地区，2018-2030年

• 介绍
• 北美洲
• 欧洲
• 亚太地区
• 拉丁美洲
• 中东和非洲

第10章竞争形势

• Roche
• Novartis
• Pfizer
• Merck
• AstraZeneca
• Bristol-Myers Squibb
• BeiGene
• Innovent Biologics
• Genentech
• AbbVie

第11章 章节

• 调查方法
• 关于出版商

The Global Atezolizumab Market size is estimated to be valued at US$ 2.68 billion in 2023 and is expected to reach US$ 7.86 billion by 2030, grow at a compound annual growth rate (CAGR) of 16.6% from 2023 to 2030.

Figure 1. Global Global Atezolizumab Market Share (%), By Region, 2022

Atezolizumab is a breakthrough immunotherapy drug that has revolutionized the treatment of cancer. It can be used alone or with other chemotherapy medications to treat certain types of non-small cell lung cancer (NSCLC) in adults. Atezolizumab injection is in a class of medications called monoclonal antibodies. This therapeutic antibody, developed by Roche, inhibits the programmed death-ligand 1 (PD-L1) protein, which enables cancer cells to evade immune system detection. By blocking PD-L1, atezolizumab unleashes the power of the immune system to recognize and attack cancer cells, leading to improved patient outcomes. Atezolizumab injection is also used in combination with other chemotherapy medications to treat certain types of small cell lung cancer (SCLC), hepatocellular carcinoma (HCC), and melanoma (a type of skin cancer) in adults. Atezolizumab is also used alone to treat certain types of alveolar soft tissue sarcomas (cancer that forms in muscles, fat, or nerves) in adults and children 2 years of age or older.

Market Dynamics:

The market for atezolizumab is experiencing significant growth, driven by several key factors. Firstly, the rising incidence of cancer globally is increasing the demand for effective treatment options. Atezolizumab has shown promising results in various cancers, including lung, bladder, and breast cancer, thus expanding the addressable patient population. Additionally, the growing awareness about the benefits of immunotherapy and the preference for targeted therapies are further bolstering market growth.

However, despite the numerous opportunities, there are certain factors restraining the market. The high cost of atezolizumab is a major barrier, limiting access to patients in lower-income countries and even in some developed markets. Additionally, the complex and lengthy regulatory approval process for new drugs poses a challenge for market entry. Moreover, the emergence of alternative immunotherapy treatments and the availability of biosimilars could also hinder market growth.

Nevertheless, the market for atezolizumab holds immense potential for future development. The ongoing research and development efforts by key players such as Novartis, Pfizer, Merck, AstraZeneca, Bristol-Myers Squibb, BeiGene, Innovent Biologics, Genentech, and AbbVie are expected to yield innovative treatment options, expanding the market further. The increasing focus on precision medicine and the development of companion diagnostics are also creating opportunities for personalized treatment approaches using atezolizumab.

Key Features of the Study:

• This report provides an in-depth analysis of the global atezolizumab market, including market size (US$ Billion) and compound annual growth rate (CAGR %) for the forecast period (2023-2030), with 2022 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
• Key players in the global atezolizumab market profiled in this study include Roche, Novartis, Pfizer, Merck, AstraZeneca, Bristol-Myers Squibb, BeiGene, Innovent Biologics, Genentech, and AbbVie
• Insights from this report would enable marketers and management authorities to make informed decisions regarding future product launches, upgrades, market expansion, and marketing tactics.
• The global atezolizumab market report caters to various stakeholders in the industry, including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders will have ease in decision-making through various strategy matrices used for analyzing the global atezolizumab market.

Atezolizumab Market Segmentation:

• By Drug Class:
  • PD-L1 Inhibitors
  • PD-1 Inhibitors
  • CTLA-4 Inhibitors
  • Immunomodulators
  • Others
• By Indication:
  • Lung Cancer
  • Bladder Cancer
  • Melanoma
  • Hodgkin's Lymphoma
  • Head and Neck Cancer
  • Others
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By End User:
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
• Top Companies in Atezolizumab Market
  • Roche
  • Novartis
  • Pfizer
  • Merck
  • AstraZeneca
  • Bristol-Myers Squibb
  • BeiGene
  • Innovent Biologics
  • Genentech
  • AbbVie

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Atezolizumab, By Drug Class
  • Market Atezolizumab, By Indication
  • Market Atezolizumab, By Distribution Channel
  • Market Atezolizumab, By End User
  • Market Atezolizumab, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
• Rising incidence of cancer globally
• Increasing demand for effective treatment options
  • Restraints
• High cost of atezolizumab
  • Opportunities
• Ongoing research and development efforts by key players
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product launch/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Global Atezolizumab Market - Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Atezolizumab Market, By Drug Class, 2018-2030, (US$ Bn)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2019 - 2030
  • Segment Trends
• PD-L1 Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• PD-1 Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• CTLA-4 Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Immunomodulators
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

6. Global Atezolizumab Market, By Indication, 2018-2030, (US$ Bn)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2019- 2030
  • Segment Trends
• Lung Cancer
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Bladder Cancer
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Melanoma
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Hodgkin's Lymphoma
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Head and Neck Cancer
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

7. Global Atezolizumab Market, By Distribution Channel, 2018-2030, (US$ Bn)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2019- 2030
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

8. Global Atezolizumab Market, By End User, 2018-2030, (US$ Bn)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2019- 2030
  • Segment Trends
• Hospitals
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Homecare
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Specialty Clinics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

9. Global Atezolizumab Market, By Region, 2018-2030, (US$ Bn)

• Introduction
  • Market Share Analysis, By Country, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, For Country 2019-2030
  • Country Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
• Middle East & Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)

10. Competitive Landscape

• Roche
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novartis
• Pfizer
• Merck
• AstraZeneca
• Bristol-Myers Squibb
• BeiGene
• Innovent Biologics
• Genentech
• AbbVie
• Analyst Views

11. Section

• Research Methodology
• About us